The COVID-19 pandemic has shown that conducting strong translational research is key to combating the coronavirus. By leveraging cutting edge laboratory techniques to study patient samples, translational research quickly pivots laboratory discoveries into new therapies for patients, in a process known as the bench-to-bedside approach. Luxembourg has established excellent transversal and translational research, spanning several research topics and disease areas and integrating the results to provide holistic and meaningful insights that can tangibly improve clinical outcomes for patients.

Dr Andy Chevigné, Group Leader of the Immuno-Pharmacology and Interactomics research group at the LIH Department of Infection and Immunity (DII), was rewarded for his outstanding contribution to the fields of allergology and molecular pharmacology through the bestowal of the “Prix du Fonds Léon et Henri Fredericq” by the Royal Academy of Science, Letters and Fine Arts of Belgium.

No Job fitting your profile right now ? this link is for you ! Feel free to send us your application!

To be part of the NORLUX Neuro-Oncology laboratory (Group leaders: Prof Simone Niclou and Dr. Anna Golebiewska) within the Department of Oncology at the LIH, we are currently looking for a Postdoctoral Fellow.

Researchers from the NORLUX Neuro-Oncology Laboratory at the LIH Department of Oncology (DONC) explored the molecular mechanisms responsible for the ability of Glioblastoma (GBM) to infiltrate and spread to healthy brain tissue. They brought forward the novel role of protein ZFAND3 in promoting the transcription of several genes that stimulate the invasion of GBM cells in the surrounding parenchyma, the functional tissue in the brain. The findings, which carry significant implications for the development of novel therapeutic strategies against GBM, were published in the international journal Nature Communications.

On December 9th, Medical & Bio Decision (MBD) announced the setup of a joint laboratory for precision medicine tailored to cancer patients, in collaboration with the Luxembourg Institute of Health (LIH) and the Integrated Biobank of Luxembourg (IBBL).

Dr Andy Chevigné and Dr Martyna Szpakowska from the LIH Department of Infection and Immunity (DII) were rewarded for their outstanding contribution to molecular pharmacology during a virtual ceremony on Tuesday, December 8th, in the presence of Frank Vandenbroucke, Belgian Minister of Public Health and Social Affairs, and of representatives of pharmaceutical companies and healthcare hubs. The Galien Prize is traditionally organised in Belgium and Luxembourg by Roularta HealthCare on a yearly basis and crowns the most significant discoveries in the fields of pharmacology, drug development and medical devices.

i2TRON is a highly innovative PhD training program on “integrating immune strategies for Translational Research in Oncology and Neurology” and is supported by the Luxembourg National Research Fund (FNR) within their PRIDE program. We will develop the next generation of translational scientists as boundary crossers, domain experts and skilled communicators. Inflammation is a common hallmark shared across different non-communicable diseases (NCD).

The Biostatistician will join the LIH’s CompetenceCenter for Methodology and Statistics (CCMS). Within the clinical research hub of theDepartment of Population Health, the CCMS provides methodological support instatistical planning, analysis & data handling for various laboratories andresearch groups. It also offers training in statistics as well as support inwriting papers.